What did @juanczunigajr actually say?
The creator laid out a week-by-week timeline for GHK-Cu, starting at "one to two milligrams a day" in weeks one and two, with no dramatic effects yet. By weeks three and four, they claim "skin texture improves" and "hair shedding decreases." By weeks five through eight, skin looks "tighter, more elastic" and "fine lines begin to soften." By weeks nine through twelve, they say "people start asking, what are you doing differently?" The framing is confident and specific, presented as if this timeline is reliably predictable for most users.
Notably, the creator does try to manage expectations upfront, saying early changes are "internal" and calling this "not a quick fix." That restraint is worth acknowledging. But specificity without evidence is still a problem, and a 12-week roadmap with week-by-week predictions implies a level of clinical certainty that simply does not exist in the published literature.
Does the science back this up?
GHK-Cu (copper peptide GHK) has legitimate in vitro and animal data behind it, but human clinical trials are thin, and none of them validate a precise week-by-week response timeline.
The peptide does appear to upregulate collagen synthesis and wound-healing pathways. Pickart and Margolina (2018, Symmetry) reviewed decades of research showing GHK-Cu stimulates collagen, elastin, and glycosaminoglycan production in fibroblast cultures. A small human study by Leyden et al. (1994, unpublished but widely cited in cosmetic literature) suggested topical GHK-Cu improved skin appearance over weeks, but the sample sizes were small and the methodology wasn't tight enough to draw firm conclusions. Anti-inflammatory effects have been demonstrated in cell studies (Pickart et al., 2012, Journal of Aging Science), but translating that to "inflammation feels noticeably better by week five" in a living human is a leap.
On hair, a 2007 study by Pyo et al. (Archives of Dermatological Research) found GHK-Cu promoted hair follicle size in mice, but human data is essentially absent. The claim that "thicker strands and early regrowth" begin by week five to eight has no human RCT supporting it.
What did they get wrong (or right)?
The creator got the underlying biology broadly right. GHK-Cu does interact with collagen synthesis pathways and has anti-inflammatory properties in controlled lab settings. Saying the body is doing something "internal" in the early weeks is actually a reasonable framing for how peptide mechanisms generally work.
Where this goes wrong is the specificity. Stating that hair shedding decreases by weeks three and four, or that fine lines soften by weeks five through eight, treats speculative extrapolation as established fact. There are no peer-reviewed human trials showing this exact timeline. The creator is likely drawing on anecdote, patient testimonials, or compounding pharmacy marketing materials, none of which constitute clinical evidence.
The dosing framing is also a problem. Referencing "one to two milligrams a day" as a starting range, and "two to three milligrams" as a maintenance range, may feel like harm reduction, but it positions specific dose windows as standard protocol. GHK-Cu dosing in humans has not been validated in rigorous clinical trials. Presenting a dose ladder as routine guidance is irresponsible without a prescribing clinician in the loop.
What should you actually know?
GHK-Cu is one of the more scientifically interesting peptides in this space, largely because its basic science is actually published and not purely theoretical. The problem is the gap between cell-culture findings and real-world human outcomes is enormous, and that gap gets papered over constantly in peptide content online.
If you are considering GHK-Cu, the honest answer is that no one can tell you with confidence that your fine lines will soften by week six, or that your hair will be thicker by week eight. Individual variation in absorption, metabolism, baseline health status, and administration method (subcutaneous injection versus topical versus intranasal) all affect outcomes significantly.
Compounded GHK-Cu also carries regulatory considerations. It is not FDA-approved as a drug for any indication. It exists in a gray zone where compounding pharmacies can prepare it for prescribers under specific conditions, but quality control and sterility standards vary. Anyone dispensing it without a licensed prescriber involved is operating outside appropriate medical practice.
The creator's closing line, that "it's your body actually repairing and rebuilding itself," is more poetic than scientific. It is not wrong, exactly, but it papers over the fact that we do not have solid human data confirming the repair mechanisms shown in vitro actually produce the cosmetic and functional outcomes described in this video.